Company intelligence / Profile preview

Lycia Therapeutics

South San Francisco, California, United Stateslyciatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lycia has developed a proprietary LYTAC platform for targeted degradation of extracellular and membrane-bound disease-causing proteins. The company has advanced several programs toward the clinic, with lead candidates focused on autoimmune and inflammatory diseases. As of May 2024, the company completed a $106.6M Series C financing to support advancement into clinical trials.

Therapeutic areas: OtherImmunologyNeurology
Modalities: LYTACs (Lysosomal Targeting Chimeras)Protein degradersPotentially other biologic modalities (platform adaptable)
Industry: Biotech

Drug pipeline

3 assets

LCA-0061

2 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly & Company (multi-year research collaboration for up to five targets in immunology/pain)

Beyond the preview

Go deeper on Lycia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lycia Therapeutics.

Explore the full profile